Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of AE-37 in patients with ovarian cancer.

Trial Profile

Phase I trial of AE-37 in patients with ovarian cancer.

Phase of Trial: Phase I

Latest Information Update: 25 Jan 2011

At a glance

  • Drugs AE 37 (Primary)
  • Indications Ovarian cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Jan 2011 Generex media release reference added
    • 03 Mar 2009 First patient dosed as reported by Generex Biotechnology media release.
    • 07 Aug 2008 Status changed from planning to recruiting as enrolment has now begun, according to Generex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top